Kymera Therapeutics (NASDAQ:KYMR) is a biotechnology firm focused on pioneering advances in targeted protein degradation (TPD) to address previously untreatable diseases. Utilizing its proprietary Pegasus platform, Kymera aims to harness the body's innate protein recycling machinery to degrade disease-causing proteins with a high degree of selectivity. The company's pipeline includes projects targeting various disorders, with a strong emphasis on immuno-oncology, inflammatory diseases, and fibrosis. Kymera is on a mission to transform the treatment landscape for patients through innovative science and strategic partnerships, aspiring to deliver a new class of highly effective therapies across multiple disease areas.